Marizomib is under clinical development by Bristol-Myers Squibb and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Marizomib’s likelihood of approval (LoA) and phase transition for Gliosarcoma took place on 03 Nov 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 03 Nov 2021 increased Marizomib’s Phase Transition Success Rate (PTSR) for Malignant Glioma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Marizomib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Marizomib overview

Marizomib (NPI-0052) is under development for the treatment of pediatric patients with diffuse intrinsic pontine glioma (DIPG), newly diagnosed malignant glioma and relapsed malignant glioma including glioblastoma and gliosarcoma. The drug candidate is administered orally, intravenously. It is a next-generation proteasome inhibitor that is isolated from Salinispora tropica, a marine actinomycete. It is a bicyclic beta-lactone gamma-lactam and targets 20S proteasome. It was also under development for the treatment of leukemia, relapsed/refractory multiple myeloma, non-small cell lung cancer, pancreatic cancer, lymphoma and melanoma.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Quick View Marizomib LOA Data

Report Segments
  • Innovator
Drug Name
  • Marizomib
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.